secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2026-08-06T11:40:21+00:00
Accession:  0001193125-26-336767
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen DSMB recommends advancing PGN-EDODM1 to 12.5 mg/kg; Q2 net loss $17.8M
-----------------------------------------------------------------------------

- DSMB recommends advancing FREEDOM2-DM1 to 12.5 mg/kg highest dose cohort; no protocol changes.
- DSMB also approves OLE dose escalation from 5 mg/kg to 10 mg/kg; 6 of 8 from 5 mg/kg cohort enrolled in OLE.
- 10 mg/kg cohort fully enrolled, 7 of 8 completed dosing; data expected November 2026.
- Q2 2026 net loss $17.8M ($0.26 per share) vs $23.1M ($0.70) in Q2 2025; R&D expenses $12.5M.
- Cash $117.2M as of June 30, 2026; sufficient into Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/0001193125-26-336767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/pepg-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer